-
公开(公告)号：US09624166B2
公开(公告)日：2017-04-18
申请号：US13391407
申请日：2010-08-27
申请人： Yonghong Deng , Louis Plamondon , Cuixiang Sun , Xiao-Yi Xiao , Jingye Zhou , Joyce A. Sutcliffe , Magnus P. Ronn
发明人： Yonghong Deng , Louis Plamondon , Cuixiang Sun , Xiao-Yi Xiao , Jingye Zhou , Joyce A. Sutcliffe , Magnus P. Ronn
IPC分类号： A61K31/65 , A61P31/04 , C07C237/26 , C07C311/08 , C07C307/10 , C07C311/09 , C07C311/13 , C07C311/21 , C07C311/29 , C07C311/44 , C07D205/04 , C07D207/12 , C07D207/16 , C07D209/44 , C07D209/52 , C07D211/54 , C07D211/60 , C07D213/70 , C07D213/74 , C07D213/82 , C07D223/06 , C07D231/18 , C07D233/60 , C07D233/84 , C07D295/15 , C07D307/64
CPC分类号： C07C311/08 , C07C237/26 , C07C307/10 , C07C311/09 , C07C311/13 , C07C311/21 , C07C311/29 , C07C311/44 , C07C2101/02 , C07C2101/04 , C07C2101/08 , C07C2101/14 , C07C2103/40 , C07C2103/44 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2603/40 , C07C2603/44 , C07C2603/46 , C07D205/04 , C07D207/12 , C07D207/16 , C07D209/44 , C07D209/52 , C07D211/54 , C07D211/60 , C07D213/70 , C07D213/74 , C07D213/82 , C07D223/06 , C07D231/18 , C07D233/60 , C07D233/84 , C07D295/15 , C07D307/64
摘要： The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.
-
公开(公告)号：US09371283B2
公开(公告)日：2016-06-21
申请号：US13075886
申请日：2011-03-30
申请人： Xiao-Yi Xiao , Roger Clark , Diana Hunt , Magnus Rönn , Louis Plamondon , Minsheng He , Joyce Sutcliffe , Trudy Grossman
发明人： Xiao-Yi Xiao , Roger Clark , Diana Hunt , Magnus Rönn , Louis Plamondon , Minsheng He , Joyce Sutcliffe , Trudy Grossman
IPC分类号： C07D209/56 , C07D209/58 , C07D221/18 , C07D243/10 , C07D405/04 , C07D405/06 , C07D487/04
CPC分类号： C07D209/58 , C07D221/18 , C07D243/10 , C07D403/06 , C07D405/04 , C07D405/06 , C07D471/04 , C07D487/04 , C07D498/04
摘要： The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.
摘要翻译： 本发明涉及由结构式（I）表示的化合物或其药学上可接受的盐。 结构式（I）的变量在本文中定义。 还描述了包含结构式（I）的化合物及其治疗用途的药物组合物。
-
公开(公告)号：US08906887B2
公开(公告)日：2014-12-09
申请号：US12462795
申请日：2009-08-07
申请人： Jingye Zhou , Xiao-Yi Xiao , Louis Plamondon , Diana Katharine Hunt , Roger B. Clark , Robert B. Zahler
发明人： Jingye Zhou , Xiao-Yi Xiao , Louis Plamondon , Diana Katharine Hunt , Roger B. Clark , Robert B. Zahler
IPC分类号： A61K31/65 , C07C237/26 , C07D233/61 , C07D207/34 , C07D295/088 , C07D211/60 , C07D257/04 , C07D295/15 , C07D209/94 , C07D231/14 , A61K45/06 , C07D207/14 , C07D333/34 , C07C311/08 , C07D231/56 , C07C311/21 , C07D207/10 , C07D413/12 , C07D213/81 , C07D249/04 , C07D261/20 , C07D207/09 , C07D239/42 , C07D333/38 , C07D277/56 , C07D207/08 , C07D231/12 , C07D207/12 , C07D213/82 , C07D205/04 , C07D295/26 , C07D207/16 , C07D261/18 , C07D211/76 , C07D213/74
CPC分类号： C07C233/57 , A61K31/65 , A61K45/06 , C07C311/08 , C07C311/21 , C07D205/04 , C07D207/06 , C07D207/08 , C07D207/09 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/34 , C07D209/94 , C07D211/60 , C07D211/76 , C07D213/74 , C07D213/81 , C07D213/82 , C07D231/12 , C07D231/14 , C07D231/56 , C07D233/61 , C07D239/42 , C07D249/04 , C07D257/04 , C07D261/18 , C07D261/20 , C07D277/56 , C07D295/088 , C07D295/12 , C07D295/15 , C07D295/26 , C07D311/08 , C07D333/34 , C07D333/38 , C07D413/12 , Y02A50/402 , Y02A50/406 , Y02A50/473 , Y02A50/478 , Y02A50/481
摘要： The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.
-
公开(公告)号：US08828988B2
公开(公告)日：2014-09-09
申请号：US13731753
申请日：2012-12-31
申请人： Roger B. Clark , Minsheng He , Louis Plamondon , Xiao-Yi Xiao , Magnus P. Rönn
发明人： Roger B. Clark , Minsheng He , Louis Plamondon , Xiao-Yi Xiao , Magnus P. Rönn
IPC分类号： A61K31/397 , A61K31/497 , A61K31/435
CPC分类号： C07D221/18
摘要： The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.
摘要翻译： 本发明涉及由结构式（I）表示的化合物或其药学上可接受的盐。 结构式I的变量在本文中定义。 还描述了包含结构式I的化合物及其治疗用途的药物组合物。
-
公开(公告)号：US20120135968A1
公开(公告)日：2012-05-31
申请号：US13319298
申请日：2010-05-07
申请人： Chi-Li Chen , Roger B. Clark , Yonghong Deng , Minsheng He , Louis Plamondon , Cuixiang Sun , Xiao-Yi Xiao , Magnus Rönn
发明人： Chi-Li Chen , Roger B. Clark , Yonghong Deng , Minsheng He , Louis Plamondon , Cuixiang Sun , Xiao-Yi Xiao , Magnus Rönn
IPC分类号： A61K31/65 , C07D207/09 , C07D295/185 , C07D211/14 , C07D211/58 , C07D209/44 , C07D205/04 , C07D295/155 , C07D209/52 , C07D213/56 , C07D207/14 , C07D471/10 , C07D307/22 , C07D307/16 , C07D487/08 , C07D217/20 , C07D279/12 , C07D225/02 , C07D223/14 , C07D223/08 , C07D223/16 , A61P31/04 , C07D295/26 , C07D241/08 , C07D211/62 , C07D401/04 , C07D221/20 , C07D209/42 , C07C237/26
CPC分类号： C07D471/10 , C07C237/26 , C07C275/24 , C07C311/06 , C07C311/19 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07C2602/08 , C07C2602/24 , C07C2602/42 , C07C2602/50 , C07C2603/46 , C07C2603/74 , C07D205/04 , C07D207/06 , C07D207/08 , C07D207/09 , C07D207/10 , C07D207/14 , C07D207/16 , C07D209/04 , C07D209/14 , C07D209/44 , C07D209/52 , C07D211/14 , C07D211/34 , C07D213/74 , C07D221/20 , C07D223/04 , C07D223/14 , C07D223/32 , C07D261/20 , C07D295/13 , C07D295/135 , C07D295/15 , C07D295/155 , C07D295/185 , C07D295/26 , C07D307/22 , C07D401/04 , C07D413/06
摘要： The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.
摘要翻译： 本发明涉及由结构式（I）表示的化合物或其药学上可接受的盐。 结构式I的变量在本文中定义。 还描述了包含结构式I的化合物及其治疗用途的药物组合物。
-
6.发明授权公开(公告)号：US08114870B2
公开(公告)日：2012-02-14
申请号：US12494677
申请日：2009-06-30
申请人： Xiao-Yi Xiao , Dinish V. Patel , John S. Ward , Mark R. Bray , Gregory E. Agoston , Anthony M. Treston
发明人： Xiao-Yi Xiao , Dinish V. Patel , John S. Ward , Mark R. Bray , Gregory E. Agoston , Anthony M. Treston
IPC分类号： A61K31/535
CPC分类号： C07D401/14 , A61K31/506 , A61K31/5377 , A61K31/541 , C07D403/12 , C07D403/14 , C07D405/14 , C07D471/04 , C07D487/04
摘要： Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.
摘要翻译： 公开了蛋白激酶抑制剂，包含这种抑制剂的组合物及其使用方法。 更具体地，公开了Aurora A（Aurora-2）蛋白激酶的抑制剂。 还公开了治疗与蛋白激酶相关疾病，特别是与Aurora-2相关的疾病如癌症的方法。
-
公开(公告)号：US07935659B2
公开(公告)日：2011-05-03
申请号：US11011452
申请日：2004-12-14
CPC分类号： C40B30/04 , B01J19/0046 , B01J2219/00295 , B01J2219/00299 , B01J2219/00308 , B01J2219/00333 , B01J2219/00344 , B01J2219/00461 , B01J2219/00463 , B01J2219/005 , B01J2219/00502 , B01J2219/0054 , B01J2219/00542 , B01J2219/00547 , B01J2219/00549 , B01J2219/00551 , B01J2219/0056 , B01J2219/00563 , B01J2219/00567 , B01J2219/00569 , B01J2219/00585 , B01J2219/0059 , B01J2219/00592 , B01J2219/00596 , B01J2219/00689 , B01J2219/00695 , B01J2219/0072 , B01J2219/00722 , B01J2219/00725 , B01L3/5027 , B01L3/502707 , B01L2300/0609 , B82Y10/00 , C07K1/00 , C07K1/04 , C07K1/047 , C40B40/06 , C40B40/10 , C40B60/08 , C40B60/14 , C40B70/00 , G01N35/00732 , G01N35/00871 , G01N2015/149 , G01N2035/00782 , G11C13/0014 , G11C13/0019 , G11C13/025
摘要： Combinations, called matrices with memories, of matrix materials with remotely addressable or remotely programmable recording devices that contain at least one data storage unit are provided. The matrix materials are those that are used in as supports in solid phase chemical and biochemical syntheses, immunoassays and hybridization reactions. The matrix materials may additionally include fluophors or other luminescent moieties to produce luminescing matrices with memories. The data storage units are non-volatile antifuse memories or volatile memories, such as EEPROMS, DRAMS or flash memory. By virtue of this combination, molecules and biological particles, such as phage and viral particles and cells, that are in proximity or in physical contact with the matrix combination can be labeled by programming the memory with identifying information and can be identified by retrieving the stored information. Combinations of matrix materials, memories, and linked molecules and biological materials are also provided. The combinations have a multiplicity of applications, including combinatorial chemistry, isolation and purification of target macromolecules, capture and detection of macromolecules for analytical purposes, selective removal of contaminants, enzymatic catalysis, cell sorting, drug delivery, chemical modification and other uses. Methods for electronically tagging molecules, biological particles and matrix support materials, immunoassays, receptor binding assays, scintillation proximity assays, non-radioactive proximity assays, and other methods are also provided.
摘要翻译： 提供了具有包含至少一个数据存储单元的具有可远程寻址或远程可编程记录设备的矩阵材料的具有存储器的组合。 基质材料是在固相化学和生物化学合成，免疫测定和杂交反应中用作载体的基质材料。 基质材料还可以包括荧光体或其它发光部分以产生具有记忆的发光基质。 数据存储单元是非易失性反熔丝存储器或易失性存储器，例如EEPROMS，DRAMS或闪存。 通过这种组合，可以通过用识别信息对存储器进行编程来标记与基质组合接近或物理接触的分子和生物颗粒，例如噬菌体和病毒颗粒和细胞，并且可以通过检索存储的 信息。 还提供了基质材料，记忆和连接分子和生物材料的组合。 这些组合具有多种应用，包括组合化学，目标大分子的分离和纯化，用于分析目的的大分子的捕获和检测，污染物的选择性去除，酶催化，细胞分选，药物递送，化学修饰和其它用途。 还提供了用于电子标记分子，生物颗粒和基质支持材料的方法，免疫测定，受体结合测定，闪烁亲近测定，非放射性邻近测定和其它方法。
-
公开(公告)号：US07790734B2
公开(公告)日：2010-09-07
申请号：US10934326
申请日：2004-09-02
申请人： Sheldon X. Cao , Jun Feng , Stephen L. Gwaltney , Stephen W. Kaldor , Jeffrey A. Stafford , Michael B. Wallace , Xiao-Yi Xiao , Zhiyuan Zhang
发明人： Sheldon X. Cao , Jun Feng , Stephen L. Gwaltney , Stephen W. Kaldor , Jeffrey A. Stafford , Michael B. Wallace , Xiao-Yi Xiao , Zhiyuan Zhang
IPC分类号： C07D239/47 , C07D239/48 , C07D403/12 , A61K31/505
CPC分类号： C07D401/04
摘要： Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula I: wherein the substituents are as described herein.
摘要翻译： 提供化合物，药物，试剂盒和方法用于包含式I的DPP-IV抑制剂：其中取代基如本文所述。
-
公开(公告)号：US07772245B2
公开(公告)日：2010-08-10
申请号：US11354594
申请日：2006-02-14
IPC分类号： A61K31/506 , C07D471/02
CPC分类号： C07D471/04 , C07D401/04 , C07D487/04 , C07D491/04 , C07D495/04
摘要： Disclosed are compounds of formula I that inhibit histone deacetylase (HDAC) enzymatic activity, pharmaceutical compositions comprising such compounds, as well as methods to treat conditions, particularly proliferative conditions, mediated at least in part by HDAC, wherein A, W, W1, W2, Ar2, and G are described herein.
摘要翻译： 公开了抑制组蛋白脱乙酰酶（HDAC）酶活性的式I化合物，包含这些化合物的药物组合物以及至少部分由HDAC介导的条件，特别是增殖性病症的方法，其中A，W，W1，W2 ，Ar2和G。
-
10.发明申请公开(公告)号：US20090264422A1
公开(公告)日：2009-10-22
申请号：US12494677
申请日：2009-06-30
申请人： Xiao-Yi Xiao , Dinish V. Patel , John S. Ward , Mark R. Bray , Gregory E. Agoston , Anthony M. Treston
发明人： Xiao-Yi Xiao , Dinish V. Patel , John S. Ward , Mark R. Bray , Gregory E. Agoston , Anthony M. Treston
IPC分类号： A61K31/541 , A61K31/496 , A61K31/506 , A61K31/5377 , A61P35/00 , A61P29/00 , A61P3/10 , A61P25/00
CPC分类号： C07D401/14 , A61K31/506 , A61K31/5377 , A61K31/541 , C07D403/12 , C07D403/14 , C07D405/14 , C07D471/04 , C07D487/04
摘要： Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.
摘要翻译： 公开了蛋白激酶抑制剂，包含这种抑制剂的组合物及其使用方法。 更具体地，公开了Aurora A（Aurora-2）蛋白激酶的抑制剂。 还公开了治疗与蛋白激酶相关疾病，特别是与Aurora-2相关的疾病如癌症的方法。
-
-
-
-
-
-
-
-
-
搜索结果
56 条记录 (耗时 0.07 秒)
